NCT01579851

Brief Summary

Sugammadex is used to reverse of a neuro-muscular block deep. It has been reported that its administration could induce signs of recovery despite continuation of anesthetic drugs. The goal of the present study is to look is the arte of this event is different according to the primary anesthetic agent used.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
71

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2012

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

January 4, 2012

Completed
4 months until next milestone

First Posted

Study publicly available on registry

April 18, 2012

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2015

Completed
Last Updated

May 22, 2017

Status Verified

May 1, 2017

Enrollment Period

3 years

First QC Date

January 4, 2012

Last Update Submit

May 19, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • Number of patients with an increase in Bispectral Index after sugammadex injection

    Increase in Bispectral Index (\> 20) after sugammadex injection

    One hour after anesthesia

  • Number of patients with occurence of clinical signs of awakening after sugammadex injection

    Clinical signs of awakening after sugammadex are wallowing, eye opening on demand, cough, spontaneous movements, response to simple commands, tearing, ...

    One hour after anesthesia

Secondary Outcomes (2)

  • T4/T1 ratio after sugammadex injection

    One hour after anesthesia

  • Number of patients with side effects due to sugammadex injection

    One hour after anesthesia

Study Arms (2)

Propofol-Remifentanil

ACTIVE COMPARATOR

Anesthesia is maintained with Propofol and Remifentanil; myorelaxation is obtained with rocuronium

Drug: Sugammadex

Sevoflurane-Remifentanil

ACTIVE COMPARATOR

Anesthesia is maintained with Sevoflurane and Remifentanil; myorelaxation is obtained with rocuronium

Drug: Sugammadex

Interventions

sugammadex * 4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count * 2 mg/kg : if there is at least two responses to Train of Four stimulations

Propofol-RemifentanilSevoflurane-Remifentanil

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adult patients scheduled to receive general anesthesia with muscle relaxation achieved with rocuronium

You may not qualify if:

  • Known drug allergy,
  • Contra-indications to the use of propofol, remifentanil, rocuronium, sevoflurane, sugammadex
  • Difficulty to use Bispectral Index monitor
  • Inability to obtain a proper monitoring of muscle relaxation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hopital Foch

Suresnes, Île-de-France Region, 92151, France

Location

MeSH Terms

Interventions

Sugammadex

Intervention Hierarchy (Ancestors)

gamma-CyclodextrinsCyclodextrinsMacrocyclic CompoundsPolycyclic CompoundsDextrinsStarchGlucansPolysaccharidesCarbohydrates

Study Officials

  • Morgan Le Guen, MD

    Hopital Foch

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 4, 2012

First Posted

April 18, 2012

Study Start

January 1, 2012

Primary Completion

January 1, 2015

Study Completion

January 1, 2015

Last Updated

May 22, 2017

Record last verified: 2017-05

Locations